| Hazard Information | Back Directory | [Uses]
Gancotamab (MM-302) is a HER2-targeted antibody-liposomal Doxorubicin conjugate with antitumor activity. Gancotamab encapsulates Doxorubicin to facilitate its delivery to HER2-overexpressing tumor cells[1]. | [in vivo]
Gancotamab (MM-302; 3 mg/kg; i.v.; every 7 days; for 3 doses) shows tumor growth inhibition and increases the expression of the DNA damage marker p-p53[1]. | Animal Model: | Seven-week-old female NCR/nu mice injected with NCI-N87 cells[1] | | Dosage: | 3 mg/kg | | Administration: | i.v.; every 7 days; for 3 doses | | Result: | Showed significantly antitumor activity. |
| [IC 50]
HER2 | [References]
[1] Christopher W Espelin, et al. Dual HER2 Targeting with Trastuzumab and Liposomal-Encapsulated Doxorubicin (MM-302) Demonstrates Synergistic Antitumor Activity in Breast and Gastric Cancer. Cancer Res. 2016 Mar 15;76(6):1517-27. DOI:10.1158/0008-5472.CAN-15-1518 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|